Sign in

    Charles Wallace

    Managing Director and Senior Equity Research Analyst at HCW

    Charles Wallace is a Managing Director and Senior Equity Research Analyst at H.C. Wainwright, specializing in biotechnology and pharmaceutical equities. He provides research coverage on companies including Sorrento Therapeutics, PDS Biotechnology, Outlook Therapeutics, and Soligenix, and his recommendations have been recognized for insightful, data-driven analysis in the sector. With over fifteen years of Wall Street experience, Wallace joined H.C. Wainwright in 2017 after previous analyst roles at firms such as Maxim Group and Cantor Fitzgerald, and he has consistently ranked among the top biotech analysts on platforms like TipRanks, posting a success rate near 60% and strong average returns for covered calls. Charles Wallace is registered with FINRA, holding securities licenses including Series 7 and Series 63, and is known for his rigorous scientific approach and in-depth industry expertise.

    Charles Wallace's questions to Evaxion (EVAX) leadership

    Charles Wallace's questions to Evaxion (EVAX) leadership • Q2 2025

    Question

    Charles Wallace from H.C. Wainwright asked about the upcoming two-year EVX-01 data presentation at ESMO, seeking details on how the clinical outcomes will compare to the one-year data and the number of patients involved in both the two-year data set and the three-year extension.

    Answer

    Birgitte Runa, Interim CEO and CSO, stated that the two-year data for EVX-01 has not yet been disclosed but confirmed that 11 patients remain active in the trial. She explained that the extension phase will involve a subset of these patients receiving EVX-01 as a monotherapy to better understand its standalone effect, with more details on patient numbers to be provided later.

    Ask Fintool Equity Research AI

    Charles Wallace's questions to electroCore (ECOR) leadership

    Charles Wallace's questions to electroCore (ECOR) leadership • Q2 2025

    Question

    Charles Wallace from HCW asked about the strategic rationale for increasing spending and delaying profitability at this time, and also questioned the contribution of Amazon sales to TRUVEGA handset revenue during the quarter.

    Answer

    CEO Daniel Goldberger explained that the timing for increased investment is ideal due to the recent sales force restructuring, promising results in the direct-to-consumer business, the integration of the Neurometrics acquisition, and the hiring of key talent like Kelly Benning and James Theophilus. Regarding Amazon, he stated that the company is still resolving logistical issues and did not have significant details to share on its sales contribution yet.

    Ask Fintool Equity Research AI

    Charles Wallace's questions to COMPUGEN (CGEN) leadership

    Charles Wallace's questions to COMPUGEN (CGEN) leadership • Q2 2025

    Question

    Charles Wallace of HCW requested more details on the planned 2026 interim analysis for the COM701 maintenance ovarian cancer study and asked if the trial is expected to be fully enrolled by that time.

    Answer

    Chief Medical Officer Dr. Michelle Mahler confirmed the study is expected to be fully enrolled by the 2026 interim analysis. She explained the analysis is designed to assess for futility and to help characterize the magnitude of COM701's effect size.

    Ask Fintool Equity Research AI